Recent preclinical studies in mouse models of leukemia have provided proof of concept for the greater benefits of combining CXCR4 inhibition with conventional chemotherapy relative to chemotherapy treatment alone [31,32]. This evidence concerns the gene CXCR4 and leukemia.